Why the study?
LVADs present challenges alongside cardiac implantable electronic devices, and data regarding leadless pacemaker use with the HeartMate 3 LVAD are limited.
Leadless pacemaker implantation is feasible in patients with a fully magnetically levitated left ventricular assist device (HeartMate 3) following the extraction of an infected cardiac device.
Answers are grounded in this paper and cite their sources.
May warrant consideration in select LVAD cases with infected devices; leaves open need for prospective safety and outcome data.
Left ventricular assist device (LVAD) therapy is increasingly used in patients with end-stage heart failure. However, LVADs are associated with challenges, especially in the presence of a cardiac implantable electronic device. Although a leadless pacemaker (PM), the Micra™ Transcatheter Pacing System, can be used with LVADs, data regarding HeartMate 3™ LVAD are limited. In this report, we present a patient with a HeartMate 3™ LVAD who underwent successful leadless PM implantation after the removal of an infected cardiac resynchronization therapy defibrillator.
No takes yet. Share an insight, caveat, or question.
Miyazaki et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: